Speaker Profile
PhD, FRSM, Chief Scientific Officer, Oxford BioDynamics
Biography
Alexandre is a molecular biologist, with the main interest in regulatory genome architecture. He is a cofounder of Oxford BioDynamics and a designer of its EpiSwitch biomarker platform. Alexandre obtained his PhD in cell biology from University College, London (with the Imperial Cancer Research Fund Laboratories). He spent six years of research at the Robert Wood Johnson Medical School UMDNJ, NJ, funded by the Howard Hughes Medical Institute. Upon return to England, he established the Nuclear Dynamics research laboratory at the Sir William Dunn School of Pathology, University of Oxford, becoming University Academic Fellow (Research Council UK) and Senior Fellow of Exeter College. Alexandre is a Fellow of the Royal Society of Medicine.
Talk
3D Genomic Liquid Biopsy: Predictive, Prognostic and Diagnostic Biomarkers
EpiSwitch 3D Genomic bloodbased platform: from fundamental biology to systemic clinical biomarkers;EpiSwitch CiRT (Checkpoint Inhibitor Response Test): clinical blood test for prediction of systemic response to PD1L1 immune checkpoint inhibitors; EpiSwitch Prostate Screening Test (PSE): highly accurate, multivariant clinical blood test for prostate cancer screening
Clinical Dx Showcase:
Oxford BioDynamics
Oxford BioDynamics Plc (OBD) is a global biotechnology company, advancing personalized healthcare by commercializing precision medicine tests. The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, built for the prediction of response to therapy, patient prognosis and disease diagnosis.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
